ZyVersa Therapeutics, Inc. cotiza a 0.08 USD y tiene una capitalización bursátil de $647674. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatm…
| Periodo | 2026-10 | 2024-11 | 2024-08 | 2024-05 |
|---|---|---|---|---|
| Real | — | $-2.43 | $-3.31 | $-4.53 |
| Estimado | — | $-1.60 | $-3.75 | $-3.70 |
| Sorpresa | — | -51.9% | +11.7% | -22.4% |
| Métrica | ZVSA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -7172.3% | -32.0% | -7140.3% |
| Current Ratio | 0.03 | 2.84 | -2.81 |
| Debt / Equity | — | 0.28 | — |